Telix Pharmaceuticals (TLX) Shares Outstanding (2023 - 2025)
Telix Pharmaceuticals (TLX) posted quarterly Shares Outstanding (Entity) of $233.9 million for Q4 2024, up 3.77% year-on-year from $225.4 million in Q1 2024, and up 3.77% on a QoQ basis from $225.4 million in Q4 2023.
Telix Pharmaceuticals (TLX) Shares Outstanding (2023 - 2025) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Shares Outstanding (Entity) for 2 consecutive years, with $233.9 million the latest figure, recorded in Q4 2024.
- Quarterly Shares Outstanding (Entity) rose 3.77% year-over-year to $233.9 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $233.9 million (up 3.77% YoY) and the FY2024 annual result came in at $233.9 million, up 3.77% from the prior year.
- Shares Outstanding (Entity) advanced to $233.9 million in Q4 2024 per TLX's latest filing, from $225.4 million in the prior quarter.
- Over the last five years, Shares Outstanding (Entity) for TLX reached as high as $233.9 million in Q4 2024 and fell as low as $225.4 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6,012.74 Bn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 47.82 Bn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.44 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 11.23 Bn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 254.10 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 104.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 400.00 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 62.19 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 198.10 Mn |
| 10 | Telix Pharmaceuticals | 3.55 Bn | 3.41 Bn | - | 337.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 337.88 Mn |
| Dec 31, 2024 | 331.23 Mn |
| Dec 31, 2023 | 319.18 Mn |